Acute promyelocytic leukemia (APL) is characterized by the t (15; 17)-associated PML-
RARA fusion gene. We have previously found that MIR125B1 is highly expressed in patients …

PML-RARα oncoprotein is a fusion protein of promyelocytic leukemia (PML) and the retinoic
acid receptor-α (RARα) and causes acute promyelocytic leukemias (APL). A hallmark of all …

Chemotherapy resistance is still a primary clinical obstacle to the successful treatment of
acute myeloid leukemia (AML). The underlying mechanisms of drug resistance are …

Objective In acute promyelocytic leukemia (APL), normal retinoid signaling is disrupted by
an abnormal PML‐RARα fusion oncoprotein, leading to a block in cell differentiation …

Autophagy is a highly conserved, closely regulated homeostatic cellular activity that allows
for the bulk degradation of long-lived proteins and cytoplasmic organelles. Its roles in cancer …

Acute promyelocytic leukemia (APL) is a distinct subset of acute myeloid leukemia (AML)
associated with peculiar biologic and clinical features and requiring specific management …

In the present study, we employed 2‐DE to characterize the effect of the acute promyelocytic
leukemia (APL)‐specific PML‐RARα fusion protein on the proteome. Differentially …

Background A hallmark of acute promyelocytic leukemia (APL) is the expression of
PML/RARα fusion protein. Treatment with all-trans retinoic acid (ATRA) results in the …

Targeting autophagy holds promise to enhance chemosensitivity in acute myeloid leukemia
(AML). MicroRNA-143 (miR-143) has been found to suppress autophagy, however, it is not …

Acute promyelocytic leukemia (APL) patients with progressive leukocytosis are more likely to
have various complications and poor outcomes. However, the regulatory roles of microRNAs …